Triple immunotherapy shows positive anticancer effect
-
Last Update: 2019-11-06
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On November 5, inovio pharmaceuticals announced that the interim analysis of a phase II study (nct03491683) to evaluate the therapeutic effect of ino-5401 + ino-9012 + cemiplimab triple therapy on newly diagnosed glioblastoma was positive Ino-5401 is a t-cell-activated immunotherapy (encoding three antigens hTERT, WT1, PSMA expressed by glioblastoma), ino-9012 is an immunoactivator encoding IL-12, and cemiplimab is a PD1 inhibitor developed by regenerant / Sanofi 52 patients were enrolled in the phase II study The data showed that 80% (16 / 20) of MGMT gene promoter methylation positive patients and 75% (14 / 32) of MGMT gene promoter methylation negative patients were in a state of no progress six months after the first dose of treatment, which exceeded the historical standard treatment Moreover, the triple therapy showed acceptable safety, tolerance and immunogenicity Most patients respond to more than one antigen encoded by ino-5401, while others respond to three antigens at the same time HTERT, WT1 and PSMA have been highlighted in a series of important cancer antigens by the National Cancer Research Institute of the United States, which have been listed as a priority in the development of cancer immunotherapy These three antigens are overexpressed and mutated frequently in various human cancers.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
